Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Recently, we published that the monoclonal antibody (D12 mAb) recognizes gp63 of , and it is responsible for COX activity. This D12 mAb exhibited cross-reactivity with , , , and . COX activity assays performed in these parasites suggested the potential presence of such enzymatic activity. In our investigation, we confirmed that wild-type recombinant gp63 exhibits COX-like activity, in contrast to a mutated recombinant gp63 variant. Consequently, our objective was to identify sequences orthologous to gp63 and subsequently analyze the binding of arachidonic acid (AA) to the putative active sites of these proteins. Given the absence of a crystallized structure for this protein in the Protein Data Bank (PDB), it was imperative to first obtain a three-dimensional structure by homology modeling, using leishmanolysin from (PDB ID: LML1) as a template in the Swiss model database. The results obtained through molecular docking simulations revealed the primary interactions of AA close to the Zinc atom present in the catalytic site of gp63-like molecules of several parasites, predominantly mediated by hydrogen bonds with HIS264, HIS268 and HIS334. Furthermore, COX activity was evaluated in commensal species such as and during the encystment process of .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11434690PMC
http://dx.doi.org/10.3390/pathogens13090718DOI Listing

Publication Analysis

Top Keywords

cox activity
12
arachidonic acid
8
d12 mab
8
recombinant gp63
8
gp63
5
activity
5
exploration binding
4
binding site
4
site arachidonic
4
acid gp63
4

Similar Publications

Background: Pneumonia is a major global public health concern. Taking antioxidant nutrients has attracted attention for their potential role in reducing pneumonia mortality. Although studies in Western countries have evaluated this association, the current evidence remains controversial, and research in Asia remains limited.

View Article and Find Full Text PDF

Wearable device-measured circadian rest-activity rhythm with mortality risk in patients with cancer.

BMJ Health Care Inform

September 2025

Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

Objectives: The objectives were to examine the associations between accelerometer-measured circadian rest-activity rhythm (CRAR), the most prominent circadian rhythm in humans and the risk of mortality from all-cause, cancer and cardiovascular disease (CVD) in patients with cancer.

Methods: 7456 cancer participants from the UK Biobank were included. All participants wore accelerometers from 2013 to 2015 and were followed up until 24 January 2024, with a median follow-up of 9.

View Article and Find Full Text PDF

Active and Passive Cardiac Index as Complementary Predictors of Outcomes After LVAD Implantation.

J Thorac Cardiovasc Surg

September 2025

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address:

Introduction: Goals of left ventricular assist device (LVAD) therapy includes low rates of right ventricular failure (RVF) and favorable survival outcomes. However, conventional metrics often fail to capture its physiologic complexity. We evaluated the prognostic utility of the Active Cardiac Index (ActCI) and Passive Cardiac Index (PasCI)-which reflect cardiac output driven by active RV contractility and passive venous return, respectively.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: Lonicera caerulea var. edulis is an Oroqen medicine with fever relief, detoxification, and anti-inflammatory activities. However, pharmacological and chemical research on its leaves is limited.

View Article and Find Full Text PDF

Background: BCMA-directed chimeric antigen receptor (CAR)-T cell therapy represents a major therapeutic breakthrough for relapsed/refractory multiple myeloma (RRMM), offering deep and durable responses in heavily pretreated patients. However, a subset of patients experience early relapse or fail to respond, highlighting the need for strategies to enhance efficacy. Gamma-secretase inhibitors (GSIs) have been shown to increase surface BCMA expression on malignant plasma cells and may potentiate the activity of BCMA CAR-T cells, particularly in patients with low baseline BCMA antigen density.

View Article and Find Full Text PDF